Actions and Spectrum:
Pretomanid (formerly known as PA-824) is a compound that is being developed as an oral antitubercular agent. It is an antimycobacterial agent that belongs to the nitroimidazole class of compounds. Pretomanid is being developed as a potential treatment for tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis that can affect the lungs and other parts of the body.
Pretomanid has a broad spectrum of activity against M. tuberculosis, including drug-resistant strains. It is active against both replicating and non-replicating bacteria, and it has the ability to penetrate into cells and tissues where the bacteria are located. In clinical trials, pretomanid has been shown to be effective in the treatment of TB when used in combination with other antitubercular agents.
Pretomanid is currently being investigated as part of a three-drug regimen for the treatment of TB called BPaL (bedaquiline, pretomanid, and linezolid). This regimen is being studied for the treatment of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), which are difficult to treat due to the resistance of the bacteria to multiple drugs.
